南美和中美人类疫苗佐剂市场预测至 2030 年 - 区域分析 - 按类型（颗粒佐剂、乳剂佐剂、组合佐剂及其他）、应用（流感、肝炎、人乳头瘤病毒 (HPV) 及其他）和最终用户（制药和生物技术公司、CMO 和 CRO 及其他）划分

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030

No. of Pages: 91    |    Report Code: BMIRE00030544    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
South & Central America Human Vaccine Adjuvants Market
Free Sample Buy Now
2022 年，南美和中美洲人类疫苗佐剂市场价值为 6362 万美元，预计到 2030 年将达到 1.8534 亿美元；预计 2022 年至 2030 年的复合年增长率为 14.3%。

个性化疫苗上升趋势推动南美和中美洲人类疫苗佐剂市场发展

精准或个性化疫苗是南美和中美洲人类疫苗佐剂市场的一个日益增长的趋势。这些疫苗针对患者疾病的特定遗传或分子特征，有助于生产针对每个患者独特免疫反应量身定制的疫苗。该技术可以潜在地提高疫苗接种的有效性和安全性，从而引起人们对用于治疗癌症、传染病和自身免疫性疾病等疾病的个性化疫苗的兴趣增加。生产个性化疫苗需要能够增强对这些定制疫苗的免疫反应的佐剂。佐剂对于刺激免疫系统对疫苗特定抗原产生有针对性的强大反应至关重要。因此，对能够有效增强个性化疫苗免疫反应的佐剂的需求日益增加。近年来，人们非常重视研发工作，以识别和创造能够有效增加个性化疫苗免疫反应的佐剂。例如，2022 年 12 月，Moderna 和 Merck 宣布推出 mRNA-4157/V940，一种研究性个性化 mRNA 癌症疫苗，与 KEYTRUDA(R)（派姆单抗）联合使用。与单独使用 KEYTRUDA 相比，使用 mRNA-4157/V940 与 KEYTRUDA 联合进行辅助治疗可将复发或死亡风险降低 44%。监管机构和医疗保健组织认识到个性化疫苗在改善公共卫生结果方面的潜力。因此，越来越多地开发能够有效改善个性化疫苗免疫反应的佐剂，从而提高疫苗的效力和安全性。这一趋势推动了南美和中美人用疫苗佐剂市场的大量创新和投资。

南美和中美人用疫苗佐剂市场概览

巴西是南美和中美最大的国家之一。根据巴西地理和统计研究所 (IBGE) 的数据，巴西拥有统一的医疗保健系统 (SUS)，可为大约 72% 的人口提供医疗服务。SUS 提供免费药物，并促进主要针对老年人和儿童的国家疫苗接种计划。据国际贸易管理局称，巴西公共实验室和大学在诊断试剂盒、药物和疫苗的研究和开发中发挥着关键作用。

根据 2020 年 10 月发布的全球疾病负担研究，巴西各种慢性病和传染病的患病率不断上升，例如结核病、中风、流感、慢性阻塞性肺病 (COPD)、阿尔茨海默病和糖尿病。同样，根据疾病预防控制中心的数据，蚊媒疾病（基孔肯雅病、登革热、疟疾、黄热病和寨卡病毒）在巴西流行。因此，由于巴西的疾病负担不断增加，人用疫苗佐剂的应用将会增加。

医疗支出的增加和老年人口的增加正在推动人用疫苗佐剂的发展。根据世界银行的数据，2020 年巴西的医疗支出占 GDP 的 10.31%，较 2015 年的 8.91% 大幅增加。此外，该国老年人口的增加使人们面临各种疾病和残疾的高风险。经合组织报告称，到 2050 年，巴西 21.9% 的人口预计将达到 65 岁及以上，较 2017 年的 8.9% 大幅增长。因此，老年人口、传染病患病率和医疗支出的增加将推动未来几年巴西人类疫苗佐剂市场的增长。

南美洲和中美洲人类疫苗佐剂市场收入及预测至 2030 年（百万美元）

南美洲和中美洲人类疫苗佐剂市场细分

南美洲和中美洲人类疫苗佐剂市场分为类型、应用、最终用户和国家。

根据类型，南美洲和中美洲人类疫苗佐剂市场分为颗粒佐剂、乳剂佐剂、组合佐剂和其他。颗粒佐剂部分在 2022 年占据了最大的市场份额。

就应用而言，南美和中美人类疫苗佐剂市场分为流感、肝炎、人乳头瘤病毒 (HPV) 等。流感部分在 2022 年占据了最大的市场份额。

按最终用户划分，南美和中美人类疫苗佐剂市场细分为制药和生物技术公司、CMO 和 CRO 等。制药和生物技术公司部分在 2022 年占据了最大的市场份额。

按国家/地区划分，南美和中美人类疫苗佐剂市场细分为巴西、阿根廷和南美和中美洲其他地区。 2022 年，巴西占据了南美和中美人类疫苗佐剂市场的主导份额。

诺华公司 (Novartis AG)、CSL 有限公司、Seppic SA、Croda International Plc、Novavax Inc 和 Phibro Animal Health Corp 是南美和中美人类疫苗佐剂市场的一些领先公司。

South & Central America Human Vaccine Adjuvants Strategic Insights

Strategic insights for South & Central America Human Vaccine Adjuvants involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/south-and-central-america-human-vaccine-adjuvants-market-strategic-framework.webp
Get more information on this report

South & Central America Human Vaccine Adjuvants Report Scope

Report Attribute Details
Market size in 2022 US$ 63.62 Million
Market Size by 2030 US$ 185.34 Million
Global CAGR (2022 - 2030) 14.3%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 类型
  • 颗粒佐剂
  • 乳化佐剂
  • 组合佐剂
By 应用
  • 流感
  • 肝炎
  • 人乳头瘤病毒
By 最终用户
  • 制药和生物技术公司
  • CMO 和 CRO
Regions and Countries Covered 南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
Market leaders and key company profiles
  • Novartis AG
  • CSL Ltd
  • Seppic SA
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp
    		•
    Get more information on this report

    South & Central America Human Vaccine Adjuvants Regional Insights

    The regional scope of South & Central America Human Vaccine Adjuvants refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/south-and-central-america-human-vaccine-adjuvants-market-geography.webp
    Get more information on this report
    Identical Market Reports with other Region/Countries

    The List of Companies - South & Central America Human Vaccine Adjuvants Market

    1. Novartis AG 
    2. CSL Ltd 
    3. Seppic SA 
    4. Croda International Plc 
    5. Novavax Inc 
    6. Phibro Animal Health Corp 

    Frequently Asked Questions
    How big is the South & Central America Human Vaccine Adjuvants Market?

    The South & Central America Human Vaccine Adjuvants Market is valued at US$ 63.62 Million in 2022, it is projected to reach US$ 185.34 Million by 2030.

    What is the CAGR for South & Central America Human Vaccine Adjuvants Market by (2022 - 2030)?

    As per our report South & Central America Human Vaccine Adjuvants Market, the market size is valued at US$ 63.62 Million in 2022, projecting it to reach US$ 185.34 Million by 2030. This translates to a CAGR of approximately 14.3% during the forecast period.

    What segments are covered in this report?

    The South & Central America Human Vaccine Adjuvants Market report typically cover these key segments-

  • 类型 (颗粒佐剂, 乳化佐剂, 组合佐剂)
  • 应用 (流感, 肝炎, 人乳头瘤病毒)
  • 最终用户 (制药和生物技术公司, CMO 和 CRO)

    • What is the historic period, base year, and forecast period taken for South & Central America Human Vaccine Adjuvants Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Human Vaccine Adjuvants Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
    • Who are the major players in South & Central America Human Vaccine Adjuvants Market?

    The South & Central America Human Vaccine Adjuvants Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Novartis AG
  • CSL Ltd
  • Seppic SA
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp
    • Who should buy this report?

    The South & Central America Human Vaccine Adjuvants Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the South & Central America Human Vaccine Adjuvants Market value chain can benefit from the information contained in a comprehensive market report.

    south-and-central-america-human-vaccine-adjuvants-market